Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunshine Biopharma has obtained the scale-up manufacturing protocol from the Contract Manufacturing Organization (CMO) to manufacture gram quantities of Adva-27a to conduct initial IND-Enabling studies.
Subscribe to our email newsletter
Adva-27a is Sunshine Biopharma’s lead anti-cancer compound that kills Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
The pre-IND-Enabling studies include in vitro biological tests and studies in live rats and mice to ensure that the scale-up manufacturing process produces a compound that is similar to the one used in the pre-clinical studies.
Sunshine Biopharma CFO Camille Sebaaly said the company is excited to be at the scale-up stage and have the capacity to manufacture gram quantities of Adva-27a compound.
"This is a very important milestone in our Adva-27a development program," Sebaaly added.